Mystic A local grassroots group, whose 117 members meet quarterly to pool their $100 contributions, has now awarded almost $200,000 to area organizations.
Power of Together 2, which formed in 2016 as an offshoot of a similar East-Lyme based group, made its latest donation $10,700 to FRESH New London last Friday.
Gae Melford, one of the group s organizers and co-founders, said that while people may donate $50 or $100 on their own to a local organization, they can have a larger impact if they pool their donations. It s exciting that you can raise $11,000 in an hour, she said, referring to the length of the group s quarterly meetings, which have been held virtually since last spring.
Published January 18. 2021 5:08PM | Updated January 19. 2021 9:22AM
Ledyard Sofia Sees Hope, a locally based nonprofit, will donate $72,000 to support research into treatments for inherited retinal diseases and to provide free access to genetic testing for those with IRDs.
The coronavirus pandemic last year forced the organization to cancel its main fundraising event, Dinner in the Dark, a well-attended dinner that has raised nearly $200,000 in previous years.
“We’re grateful that we still had a pretty successful year,” Laura Manfre, the organization’s co-founder and board president, said in a news release. “The global pandemic made fundraising challenging for all nonprofits, but we were able to pivot with the help of our terrific team, made up of staff, volunteers and our board of directors. This allowed us to continue our commitment to funding research into treatments for inherited retinal disease.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
ProQR Therapeutics N.V.January 7, 2021 GMT
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Phase 2/3